Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats
Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats
复制标题
DOI：
10.1023/a:1022572727408
复制
发表时间：
2003-03-01
影响因子：
9.1
通讯作者：
Xiao, BG
中科院分区：
文献类型：
--
作者：
Duan, RS;Link, H;Xiao, BG
为探讨脱氢表雄酮(DHEA)在实验性自身免疫性重症肌无力(EAMG)发病机制中的作用，从免疫后第4天起隔天给Lewis大鼠注射脱氢表雄酮(DHEA)0.5 mg/只。至第35天P.I.使用鱼雷乙酰胆碱受体(AChR)和弗洛因德完全佐剂。接受DHEA治疗的大鼠的临床评分较低(平均临床评分为2分，而第37天为0.5分)。体重下降(平均体重为169克，第37天为142克)。与对照组EAMG大鼠比较。DHEA治疗后第7、14、21天血清抗AChR-Ig G和Ig G2b抗体滴度降低。抑制抗AChR抗体分泌细胞(60%)，同时伴有IL-4降低(33%)，淋巴结单个核细胞中转化生长因子-β1阳性细胞增多(41%)。在Lewis大鼠的EAMG中获得的这些结果进一步鼓励我们研究DHEA对人MG的治疗。
To detect a possible effect of dehydroepiandrosterone (DHEA) in the pathogenesis of experimental autoimmune myasthenia gravis (EAMG), DHEA( 0.5 mg/rat) was administrated intraperitoneally to Lewis rats every other day from day 4 postimmunization (p.i.) to day 35 p.i. with Torpedo acetylcholine receptor (AChR) and Freund's complete adjuvant. Rats treated with DHEA had a lower clinical score (mean clinic score, 2 versus 0.5 on day 37 p.i.) and a lower body weight loss (mean body weight, 169 versus 142 g on day 37 p.i.) compared with control EAMG rats. DHEA treatment decreased serum anti-AChR IgG and IgG2b antibody titers on days 7, 14, and 21 p.i. and inhibited the levels of anti-AChR IgG antibody secreting cells (60%), accompanied by decreased IL-4 (33%) and augmented TGF-beta1-positive cells (41%) among lymph node mononuclear cells. These results obtained from EAMG in Lewis rats further encourage us to study DHEA treatment in human MG.